Powered By
I just read a few comments regarding Talquetamab + Daratumumab (Tal-Dara) trial treatment and the effectiveness of using this bispecific with Dara. The drug combo is still in the trial phase and although its response is promising, it’s unlikely to be fast tracked by the FDA for 2nd line treatment anytime soon. I like looking at data, so here’s a table I generated comparing Talquetamab + Daratumumab (Tal-Dara) [in trial] vs. Teclistamab + Daratumumab (Tec-Dara) [FDA approved 1st qt 2026] side by… read more
I’ll give it a few more shots to upload a cleaner version of the file.
Jamie,
I wish I could read it. Sometimes text gets blurry. I’m not sure why. @A MyMyelomaTeam Member was in the Talquetamab and Daratumamab trial at City of Hope in Duarte and has had a complete response. This is very encouraging.
Paula🌹
Sorry for the blurry photo. Definitely not blurry before it’s uploaded!
JamieW, thank you for using your analytic skills to help put this information into an easier to compare format. The phase 3 trial preliminary results are amazing as you said and so very promising. All of the current new and emerging treatments and combinations only add to my optimism for very good outcomes for us all. Lyn
Join
Your Privacy Choices
